UPDATE 1-Roche's lung cancer combo treatment wins FDA approval

Swiss drugmaker Roche Holding AG said on Thursday that its Tecentriq immunotherapy in combination with Avastin and chemotherapy was approved by the U.S. Food and Drug Administration as a first-line treatment for a type of lung cancer.